The Safety and Feasibility of Radiofrequency Ablation to Treat Low-risk Thyroid Cancer

Launched by UNIVERSITY HEALTH NETWORK, TORONTO · Apr 8, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at a treatment called radiofrequency ablation (RFA) for patients with low-risk thyroid cancer that is 2 centimeters or smaller. The main goal is to see how practical and safe this treatment is for these types of thyroid cancers. If you qualify and decide to participate, you will first have some scans to examine the thyroid nodule. Then, you will undergo the RFA procedure, which uses heat to shrink or destroy the cancer cells. After the procedure, you will have three follow-up appointments to check on your health at 4 weeks, 6 months, and 12 months.

To participate in this trial, you need to be at least 18 years old and have a thyroid nodule that is less than or equal to 2 cm in size, specifically classified as Bethesda 5 or 6 (which indicates a certain level of concern about the nodule). You also need to be able to provide consent and attend the follow-up appointments. However, this trial is not for individuals under 18, pregnant women, or those with more serious types of thyroid cancer. If you meet these criteria, this trial could offer a new way to treat your thyroid cancer with minimal invasiveness.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• 1. Patients with:
• • Nodule less than or equal to 2cm in size
• • a. Specifically: Bethesda 5/6
• • Their age is ≥18 years and ≤100 years
• • Able to provide written consent
• • Able to attend required follow-ups as per the protocol
• Exclusion Criteria:
• • Patients \<18 years old
• • Pregnant women
• • Any concern for invasive or metastatic thyroid cancer
• • Previously treated for thyroid cancer